Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts ...

Danish drugmaker Novo Nordisk has fast-tracked the India launch of its blockbuster anti-obesity drug Wegovy (semaglutide 2.4 ...

While the makers of Ozempic have stated that its GLP-1 medication was not made to be used as a weight loss drug, nor should ...

Plain Facts compilation, we present to you data-based insights, with easy-to-read charts, to help you delve deeper into the ...

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, improving satiety and reducing cravings for food, ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

Wegovy will be available in a once-weekly innovative pen device in five dose strengths – 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a ...

Wegovy is being made available in five dosing strengths with an easy-to-use pen device, which does away the use of syringes ...

Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a ...